-+ 0.00%
-+ 0.00%
-+ 0.00%

Brookline Capital Initiates Coverage On Radiopharm Theranostics with Buy Rating, Announces Price Target of $18

Benzinga·07/21/2025 12:33:57
Listen to the news
Brookline Capital analyst Kemp Dolliver initiates coverage on Radiopharm Theranostics (NASDAQ:RADX) with a Buy rating and announces Price Target of $18.